Anaptysbio (ANAB) Net Cash Flow Growth (3y) (2019 - 2026)
Anaptysbio (ANAB) Net Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-13.44% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Anaptysbio |
1.66 Bn |
1.38 Bn |
- |
-23.84% |
| Date | Value |
|---|
| Mar 31, 2026 |
-23.84% |
| Dec 31, 2025 |
115.87% |
| Sep 30, 2025 |
91.13% |
| Jun 30, 2025 |
16.91% |
| Mar 31, 2025 |
57.97% |
| Dec 31, 2024 |
-34.44% |
| Sep 30, 2024 |
208.62% |
| Jun 30, 2024 |
-27.77% |
| Mar 31, 2024 |
-19.27% |
| Dec 31, 2023 |
-38.37% |
| Sep 30, 2023 |
9.49% |
| Jun 30, 2023 |
-45.22% |
| Mar 31, 2023 |
82.51% |
| Dec 31, 2022 |
45.40% |
| Sep 30, 2022 |
-33.17% |
| Jun 30, 2022 |
-62.95% |
| Mar 31, 2022 |
-249.06% |
| Dec 31, 2021 |
42.38% |
| Sep 30, 2021 |
-74.17% |
| Jun 30, 2021 |
80.43% |
